Comparative Pharmacology
Head-to-head clinical analysis: DELATESTRYL versus ORETON METHYL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DELATESTRYL versus ORETON METHYL.
DELATESTRYL vs ORETON METHYL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Testosterone ester; binds to androgen receptors, activating gene transcription and promoting protein synthesis, muscle growth, and secondary sexual characteristics.
Methyltestosterone is a synthetic androgen that binds to androgen receptors, activating transcription of androgen-responsive genes, leading to increased protein synthesis, muscle growth, and secondary sexual characteristic development.
50 to 200 mg intramuscularly every 2 to 4 weeks.
10-50 mg orally or buccally 1-3 times daily; or 25-100 mg IM every 2-4 weeks.
None Documented
None Documented
8 days (terminal); requires 5-6 weeks to reach steady state with weekly dosing
Terminal half-life approximately 2.7–3.8 hours; brief due to rapid hepatic metabolism.
Urinary (90% as glucuronide and sulfate conjugates, 5% as unchanged drug); fecal (5%)
Primarily renal as conjugated metabolites; ~90% urinary, ~6% fecal within 4 days.
Category C
Category C
Androgen
Androgen